| Exclusion Criteria: | 1) Current or prior history of central nervous system (CNS) metastases
2) Prior history of other primary cancer unless: - Curatively resected non-melanomatous skin cancer - Curatively treated cervical carcinoma in situ - Other solid tumor curatively treated with no known active disease present and no curative treatment administered for the last 3 years
3) Prior chemotherapy as follows: - Any prior chemotherapy for advanced NSCLC - Any prior adjuvant chemotherapy for NSCLC within 52 weeks prior to randomization. Adjuvant chemotherapy completed > 52 weeks prior to randomization is permitted - Any prior chemoradiation for locally advanced stage III disease
4) Prior radiation therapy as follows: - central (chest) radiation therapy within 28 days prior to randomization - other radiation therapy within 14 days prior to randomization - radiation therapy to a site of measurable disease unless there has been documented disease progression
5) History of pulmonary hemorrhage or gross hemoptysis (˝ teaspoon of bright red blood or more) within 6 months prior to randomization
6) Prior targeted therapies, including but not limited to: - AMG 706, inhibitors of VEGF (eg, SU5416, SU6668, AZ6474, SU11248, PTK787, AZD2171, AEE-788, BAY 43-9006, bevacizumab), or EGFr (eg, cetuximab, gefitinib, erlotinib)
7) Known history of allergy or hypersensitivity reaction to paclitaxel or carboplatin
8) Any anticoagulation therapy within 7 days prior to randomization except the use of low-dose warfarin < 2 mg daily] or low molecular weight heparin or heparin flushes for prophylaxis against central venous catheter thrombosis which is allowed
9) Chronic daily treatment with aspirin (> 325 mg/day) or non-steroidal anti-inflammatory agents known to inhibit platelet function. Treatment with dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix) and/or cilostazol (Pletal) is also not allowed
10) History of arterial or venous thrombosis within 52 weeks prior to randomization
11) History of bleeding diathesis or non-pulmonary bleeding within 14 days prior to randomization
12) Peripheral neuropathy > grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0
13) Myocardial infarction, grade 2 or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure, percutaneous transluminal coronary angioplasty/stent, ongoing arrythmias requiring medication or unstable angina within 52 weeks prior to randomization
14) Any kind of disorder that compromises the ability to comply with the study procedures
15) Uncontrolled hypertension as defined by resting blood pressure >140/90 mm Hg. Anti-hypertensive medications are allowed if hypertension is stably controlled at the time of randomization
16) Surgery: - Major surgery within 30 days prior to randomization - Minor surgery within 14 days prior to randomization - Failure to recover from prior surgery - Planned elective surgery while on study - Placement of central catheter within 7 days prior to randomization - Core needle biopsy within 7 days prior to randomization
17) Not recovered from all previous therapies (ie, radiation, surgery and medications). CTCAE grade at screening must be ≤ Grade 1 or the subject's baseline prior to their most recent previous therapy
18) Open wound, ulcer or fracture
19) Active infection requiring systemic treatment or any uncontrolled infection ≤ 14 days prior to randomization
20) Participation in therapeutic clinical trials or currently receiving other investigational treatment(s) within 30 days prior to randomization
21) Pregnant (eg, positive HCG test) or breast feeding woman
22) Man or woman not consenting to use adequate contraceptive precautions (eg, hormonal, barrier or abstinence) during the course of the study and for 6 months after the last treatment
23) Known to be human immunodeficiency virus (HIV), hepatitis B surface antigen or hepatitis C positive
24) History of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risks associated with the study participation or investigational product(s) administration or may interfere with the interpretation of the results
25) Previously randomized into this study
26) Not available for follow-up assessments or unable to comply with study requirements
|